TrialCancer immunology research2024

Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer.

Atish D Choudhury et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.